

Yoshiharu Tsubakihara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2252522/publications.pdf>

Version: 2024-02-01

115
papers

5,758
citations

61857

43
h-index

82410

72
g-index

115
all docs

115
docs citations

115
times ranked

4527
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 110-119.	0.7	4
2	Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. <i>American Journal of Nephrology</i> , 2021, 52, 26-35.	1.4	37
3	Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1946.	3.8	37
4	Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2Ã—2 factorial, open-label, randomized clinical trial. <i>Transplant International</i> , 2021, 34, 1212-1225.	0.8	8
5	A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 108-114.	0.4	36
6	Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial. <i>Scientific Reports</i> , 2020, 10, 15500.	1.6	6
7	Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients. <i>Scientific Reports</i> , 2020, 10, 13766.	1.6	5
8	Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 608-615.	2.2	10
9	Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. <i>Scientific Reports</i> , 2019, 9, 14871.	1.6	24
10	Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 231-243.	0.7	9
11	Rationale and design of observational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetin alfa (BRIGHTEN Trial). <i>Clinical and Experimental Nephrology</i> , 2018, 22, 78-84.	0.7	6
12	Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2325.	3.8	55
13	Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials. <i>Nephrology</i> , 2017, 22, 769-775.	0.7	7
14	Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching. <i>Scientific Reports</i> , 2017, 7, 41170.	1.6	15
15	2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. <i>Renal Replacement Therapy</i> , 2017, 3, .	0.3	137
16	Different impact of hemodialysis vintage on cause-specific mortality in long-term hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv402.	0.4	31
17	Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry. <i>PLoS ONE</i> , 2016, 11, e0156951.	1.1	23
18	Serum Creatinine Modifies Associations between Body Mass Index and Mortality and Morbidity in Prevalent Hemodialysis Patients. <i>PLoS ONE</i> , 2016, 11, e0150003.	1.1	20

#	ARTICLE	IF	CITATIONS
19	Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Coâ€¦ET Study. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 598-607.	0.4	6
20	A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 885-895.	0.7	13
21	Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 595-602.	0.4	54
22	Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). <i>Clinical and Experimental Nephrology</i> , 2016, 20, 71-76.	0.7	7
23	Japanese Society for Dialysis Therapy Clinical Guideline for â€œHemodialysis Initiation for Maintenance Hemodialysisâ€¦. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 93-107.	0.4	61
24	Use of Vitamin <sc>D</sc> Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 235-244.	0.4	16
25	Institutional factors influencing regional differences in the 1-year survival of dialysis patients. <i>Hemodialysis International</i> , 2015, 19, S5-S10.	0.4	1
26	High Hemoglobin Levels Maintained by an Erythropoiesisâ€¦stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 457-465.	0.4	18
27	Predialysis and Postdialysis pH and Bicarbonate and Risk of All-Cause and Cardiovascular Mortality in Long-term Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2015, 66, 469-478.	2.1	46
28	<i>ACE</i> insertion/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade in patients with IgA nephropathy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 633-641.	1.0	12
29	Dialysis Fluid Endotoxin Level and Mortality in Maintenance Hemodialysis: A Nationwide Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 899-904.	2.1	51
30	Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype. <i>Kidney International</i> , 2015, 88, 1013-1029.	2.6	25
31	Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease. <i>Kidney International</i> , 2015, 88, 833-842.	2.6	56
32	Japanese society for dialysis therapy renal data registryâ€¦a window through which we can view the details of Japanese dialysis population. <i>Kidney International Supplements</i> , 2015, 5, 15-22.	4.6	70
33	Thresholds of iron markers for iron deficiency erythropoiesisâ€¦finding of the Japanese nationwide dialysis registry. <i>Kidney International Supplements</i> , 2015, 5, 23-32.	4.6	28
34	The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry. <i>PLoS ONE</i> , 2015, 10, e0143430.	1.1	27
35	Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. <i>PLoS ONE</i> , 2014, 9, e114678.	1.1	17
36	Magnesium Modifies the Cardiovascular Mortality Risk Associated with Hyperphosphatemia in Patients Undergoing Hemodialysis: A Cohort Study. <i>PLoS ONE</i> , 2014, 9, e116273.	1.1	81

#	ARTICLE	IF	CITATIONS
37	A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1532-1538.	0.4	80
38	Carpal Tunnel Surgery as Proxy for Dialysis-Related Amyloidosis: Results from the Japanese Society for Dialysis Therapy. <i>American Journal of Nephrology</i> , 2014, 39, 449-458.	1.4	32
39	Regional Variation in Hip Fracture Incidence Among Japanese Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 162-166.	0.4	15
40	Low Hemoglobin Levels and Hyporesponsiveness to Erythropoiesis-Stimulating Agent Associated With Poor Survival in Incident Japanese Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 404-413.	0.4	33
41	Impacts of Recombinant Human Erythropoietin Treatment During Predialysis Periods on the Progression of Chronic Kidney Disease in a Large-scale Cohort Study (C-JET) Tj ETQq0.4 0.784384 rgBT	0.4	34
42	Does Hypomagnesemia Predict Faster Progression of Nondiabetic Chronic Kidney Disease?. <i>American Journal of Medicine</i> , 2014, 127, e13.	0.6	2
43	Vitamin D Deficiency Predicts Decline in Kidney Allograft Function: A Prospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 527-535.	1.8	52
44	Dietary L-Lysine Prevents Arterial Calcification in Adenine-Induced Uremic Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1954-1965.	3.0	47
45	An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2012). <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 535-602.	0.4	115
46	Clinical Practice Guideline for the Management of Chronic Kidney Disease—Mineral and Bone Disorder. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 247-288.	0.4	305
47	Increased risk of hip fracture among Japanese hemodialysis patients. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 315-321.	1.3	106
48	Factors associated with the incidence of dialysis. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 890-898.	0.7	4
49	Overview of Regular Dialysis Treatment in Japan (as of 31 December 2011). <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 567-611.	0.4	132
50	Effect of anemia correction to the modestly high hemoglobin level in patients with chronic kidney disease on left ventricular hypertrophy. <i>Journal of Cardiology</i> , 2013, 62, 249-256.	0.8	26
51	Association of Nocturnal Hypoxemia with Progression of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1502-1507.	2.2	52
52	Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 294-303.	0.7	9
53	Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 221-228.	0.4	133
54	Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. <i>Kidney International Supplements</i> , 2013, 3, 469-475.	4.6	20

#	ARTICLE	IF	CITATIONS
55	Combined Use of Vitamin D Status and FGF23 for Risk Stratification of Renal Outcome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 810-819.	2.2	110
56	Orally Active Vitamin D for Potential Chemoprevention of Posttransplant Malignancy. <i>Cancer Prevention Research</i> , 2012, 5, 1229-1235.	0.7	17
57	A candidate gene approach to genetic contributors to the development of IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1020-1030.	0.4	17
58	Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4378-4385.	0.4	14
59	Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1076-1083.	0.4	62
60	Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. <i>Bone</i> , 2012, 50, 1266-1274.	1.4	76
61	Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 387-435.	0.4	109
62	An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2010). <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 483-521.	0.4	111
63	Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. <i>Laboratory Investigation</i> , 2012, 92, 1686-1697.	1.7	37
64	Reply to "FGF23 adds value to risk prediction in patients with chronic kidney disease". <i>Bone</i> , 2012, 51, 832-833.	1.4	2
65	Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation. <i>Bone</i> , 2012, 51, 729-736.	1.4	21
66	Effects of Anemia Correction by Erythropoiesis-Stimulating Agents on Cardiovascular Function in Non-Dialysis Patients With Chronic Kidney Disease. <i>International Heart Journal</i> , 2012, 53, 238-243.	0.5	24
67	Hypomagnesemia in Type 2 Diabetic Nephropathy. <i>Diabetes Care</i> , 2012, 35, 1591-1597.	4.3	103
68	Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 250-258.	0.7	13
69	Ideal Timing and Predialysis Nephrology Care Duration for Dialysis Initiation: From Analysis of Japanese Dialysis Initiation Survey. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 54-62.	0.4	32
70	Overview of Regular Dialysis Treatment in Japan (as of 31 December 2009). <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 11-53.	0.4	83
71	Erythropoiesis-Stimulating Agent Responsiveness and Mortality in Hemodialysis Patients: Results from a Cohort Study From the Dialysis Registry in Japan. <i>American Journal of Kidney Diseases</i> , 2012, 59, 108-116.	2.1	91
72	Quiz Page April 2012. <i>American Journal of Kidney Diseases</i> , 2012, 59, A33-A36.	2.1	2

#	ARTICLE	IF	CITATIONS
73	Late Dialysis Start Did Not Affect Long-Term Outcome in Japanese Dialysis Patients: Long-Term Prognosis From Japanese Society of Dialysis Therapy Registry. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 111-120.	0.4	34
74	High Target Hemoglobin With Erythropoiesis-Stimulating Agents Has Advantages in the Renal Function of Non-Dialysis Chronic Kidney Disease Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 529-540.	0.4	57
75	Understanding Measurements of Vitality in Patients with Chronic Kidney Disease: Connecting a Quality-of-Life Scale to Daily Activities. <i>PLoS ONE</i> , 2012, 7, e40455.	1.1	8
76	Urinary Type IV Collagen in Nondiabetic Kidney Disease. <i>Nephron Clinical Practice</i> , 2011, 117, c160-c166.	2.3	18
77	Limiting Iron Supplementation for Anemia in Dialysis Patients—The Basis for Japan's Conservative Guidelines. <i>Seminars in Dialysis</i> , 2011, 24, 269-271.	0.7	19
78	Guideline—Practice Gap in the Management of Predialysis Chronic Kidney Disease Mineral Bone Disorder in Japan. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 2-8.	0.4	13
79	Positive Outcomes of High Hemoglobin Target in Patients With Chronic Kidney Disease Not on Dialysis: A Randomized Controlled Study. <i>Therapeutic Apheresis and Dialysis</i> , 2011, 15, 431-440.	0.4	42
80	An autopsy-proven case of myeloperoxidase-antineutrophil cytoplasmic antibody-positive polyarteritis nodosa with acute renal failure and alveolar hemorrhage. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 281-284.	0.7	10
81	High Prevalence of Obstructive Sleep Apnea and Its Association with Renal Function among Nondialysis Chronic Kidney Disease Patients in Japan. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 995-1000.	2.2	108
82	Elevated Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Predicts Atherosclerotic Cardiovascular Events in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1112-1120.	2.2	105
83	Tachycardia as a predictor of poor survival in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 963-969.	0.4	30
84	Factors influencing regional differences in the outcome of dialysis in Japan. <i>Nihon Toseki Igakkai Zasshi</i> , 2011, 44, 681-688.	0.2	2
85	To Treat or Not To Treat Renal Anemia of Chronic Kidney Disease Patients?. <i>Therapeutic Apheresis and Dialysis</i> , 2010, 14, 235-239.	0.4	0
86	Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. <i>Clinical and Experimental Nephrology</i> , 2010, 14, 28-35.	0.7	25
87	Design and methods of a strategic outcome study for chronic kidney disease: Frontier of Renal Outcome Modifications in Japan. <i>Clinical and Experimental Nephrology</i> , 2010, 14, 144-151.	0.7	22
88	2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. <i>Therapeutic Apheresis and Dialysis</i> , 2010, 14, 240-275.	0.4	211
89	Overview of Regular Dialysis Treatment in Japan (as of 31 December 2008). <i>Therapeutic Apheresis and Dialysis</i> , 2010, 14, 505-540.	0.4	151
90	The relationship between hemodialysis prescription/dose and patient mortality. <i>Nihon Toseki Igakkai Zasshi</i> , 2010, 43, 551-559.	0.2	3

#	ARTICLE	IF	CITATIONS
91	Cigarette Smoking and Progression of IgA Nephropathy. American Journal of Kidney Diseases, 2010, 56, 313-324.	2.1	84
92	Bacteriological Water Quality in the Central Dialysis Fluid Delivery System from the Survey of the Japanese Society for Dialysis Therapy. Blood Purification, 2009, 27, 11-16.	0.9	20
93	A candidate gene approach to genetic prognostic factors of IgA nephropathy—a result of Polymorphism REsearch to Distinguish genetic factors Contributing To progression of IgA Nephropathy (PREDICT-IgAN). Nephrology Dialysis Transplantation, 2009, 24, 3686-3694.	0.4	19
94	ROS and PDGF- β receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. American Journal of Physiology - Cell Physiology, 2009, 297, C389-C396.	2.1	90
95	An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2007). Therapeutic Apheresis and Dialysis, 2009, 13, 457-504.	0.4	90
96	Effects of Serum Calcium, Phosphorous, and Intact Parathyroid Hormone Levels on Survival in Chronic Hemodialysis Patients in Japan. Therapeutic Apheresis and Dialysis, 2008, 12, 49-54.	0.4	88
97	Overview of Regular Dialysis Treatment in Japan as of 31 December 2006. Therapeutic Apheresis and Dialysis, 2008, 12, 428-456.	0.4	63
98	Bacteriological Qualities of Dialysis Fluid in Japan as of 31 December 2006. Therapeutic Apheresis and Dialysis, 2008, 12, 457-463.	0.4	17
99	Reverse epidemiology in hemodialysis patients. Lessons from Japanese registries. Nephrologie Et Therapeutique, 2008, 4, 223-227.	0.2	3
100	Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker. Hypertension Research, 2008, 31, 59-67.	1.5	90
101	Baseline characteristics and anemia treatment for new hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2008, 41, 251-254.	0.2	5
102	Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan. Nephrology Dialysis Transplantation, 2007, 23, 984-990.	0.4	17
103	Prospective Randomized Study Evaluating the Efficacy of the Spherical Adsorptive Carbon AST-120 in Chronic Kidney Disease Patients with Moderate Decrease in Renal Function. Nephron Clinical Practice, 2007, 105, c99-c107.	2.3	68
104	Overview of Regular Dialysis Treatment in Japan (as of 31 December 2005). Therapeutic Apheresis and Dialysis, 2007, 11, 411-441.	0.4	56
105	Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy. Clinical and Experimental Nephrology, 2006, 10, 40-54.	0.7	11
106	Prevalence of human polyoma virus (BK virus and JC virus) infection in patients with chronic renal disease. Clinical and Experimental Nephrology, 2005, 9, 132-137.	0.7	17
107	Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney International, 2004, 66, 1212-1220.	2.6	530
108	2004 Japanese Society for Dialysis Therapy Guidelines for Renal Anemia in Chronic Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2004, 8, 443-459.	0.4	67

#	ARTICLE	IF	CITATIONS
109	Carbonic adsorbent AST-120 retards progression of renal failure by additive effect with ACEI and protein restriction diet. <i>Clinical and Experimental Nephrology</i> , 2003, 7, 113-119.	0.7	7
110	Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients. <i>American Journal of Kidney Diseases</i> , 2003, 41, S38-S41.	2.1	23
111	Effects of <i>L</i> -Threo-3,4-Dihydroxyphenylserine on Orthostatic Hypotension in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2002, 22, 338-346.	1.4	16
112	Significantly Rapid Relief from Steroid-Resistant Nephrotic Syndrome by LDL Apheresis Compared with Steroid Monotherapy. <i>Nephron</i> , 2001, 89, 408-415.	0.9	58
113	Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. <i>American Journal of Kidney Diseases</i> , 2000, 35, 250-256.	2.1	247
114	Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. <i>Clinical Therapeutics</i> , 1997, 19, 487-497.	1.1	14
115	Identification and characterization of membrane cofactor protein (CD46) in the human kidneys. <i>European Journal of Immunology</i> , 1994, 24, 1529-1535.	1.6	36